Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism

Eirini Maratou1, Dimitrios J Hadjidakis2, Melpomeni Peppa3, Maria Alevizaki1, Katerina Tsegka2, Vaia Lambadiari2, Panayota Mitrou3, Eleni Boutati2, Anastasios Kollias2, Theofanis Economopoulos2, Sotirios A Raptis1,2 and George Dimitriadis3

1Hellenic National Center for Research, Prevention and Treatment of Diabetes Mellitus and its Complications (HNDC), GR-10675 Athens, Greece. 2Second Department of Internal Medicine, Research Institute and Diabetes Center, ‘Attikon’ University Hospital, Athens University, 1 Rimini Street, GR-12462 Haidari, Greece. 3Endocrine Unit, Department of Clinical Therapeutics, Athens University, GR-11528 Athens, Greece (Correspondence should be addressed to G Dimitriadis; Email: gdimitr@med.uoa.gr)

Abstract

Objective: Although clinical hyperthyroidism (HR) is associated with insulin resistance, the information on insulin action in subclinical hyperthyroidism (SHR) is limited.

Design and methods: To investigate this, we assessed the sensitivity of glucose metabolism to insulin in vivo (by an oral glucose tolerance test) and in vitro (by measuring insulin-stimulated rates of glucose transport in isolated monocytes) in 12 euthyroid subjects (EU), 16 patients with HR, and 10 patients with SHR.

Results: HR and SHR patients displayed higher postprandial glucose levels (area under the curve, AUC0–100 32 190±1067 and 31 497±716 mg/dl min respectively) versus EU (27 119±1156 mg/dl min, P<0.05). HR but not SHR patients displayed higher postprandial insulin levels (AUC0–100 11 020±985 and 9565±904 mU/l min respectively) compared with EU subjects (AUC0–100 7 588±743 mU/l min, P<0.05). Homeostasis model assessment index was increased in HR and SHR patients (2.81±0.3 and 2.43±0.38 respectively) compared with EU subjects (1.27±0.16, P<0.05), while Matsuda and Belfiore indices were decreased in HR (4.21±0.41 and 0.77±0.05 respectively, P<0.001) and SHR patients (4.47±0.33 and 0.85±0.05 respectively, P<0.05 versus EU (7.76±0.87 and 1 respectively). At 100 μU/ml insulin, i) GLUT3 levels on the monocyte plasma membrane were increased in HR (468.8±7 mean fluorescence intensity (MFI)) and SHR patients (522.2±25 MFI) compared with EU subjects (407±18 MFI, P<0.01 and P<0.05 respectively), ii) glucose transport rates in monocytes (increases from baseline) were decreased in HR patients (37.8±5%) versus EU subjects (61.2±10%, P<0.05).

Conclusions: Insulin-stimulated glucose transport in isolated monocytes of patients with HR was decreased compared with EU subjects. Insulin resistance was comparable in patients with both HR and SHR.

European Journal of Endocrinology 163 625–630

Introduction

In clinical hyperthyroidism (HR), impaired glucose tolerance and insulin resistance are frequent findings (1–5). In HR, tissue metabolic rate increases significantly (1). To adapt to high energy demand, the liver must increase the rate of lactate formation and glucose oxidation: lactate is then used by the liver to increase the rate of gluconeogenesis and endogenous glucose production (1, 2).

Subclinical hyperthyroidism (SHR) is defined as decreased plasma TSH levels in the presence of normal levels of free thyroxine (FT4) and free triiodothyronine (FT3). SHR can be caused by exogenous or endogenous factors (6) and may be transient or persistent. The studies in the literature regarding insulin resistance in SHR are scarce and controversial. Insulin sensitivity in patients with iatrogenic SHR has been reported to be either reduced (7, 8) or unaltered (9). In SHR subjects, relevant changes in cardiovascular measures, such as arrhythmias, increased left ventricular mass, and impaired left ventricular mass function, have been recently reported; these changes are often accompanied by impaired diastolic function and, sometimes by reduced systolic performance on effort and decreased exercise tolerance, abnormalities that usually precede the onset of severe cardiovascular disease (10).

This study was undertaken in patients with HR and SHR to examine the sensitivity of glucose metabolism to insulin both in vivo (by an oral glucose tolerance test (OGTT)) and in vitro (by measuring insulin-stimulated rates of glucose transport in isolated monocytes).
Materials and methods

Subjects

The groups participating in the study were i) newly diagnosed clinical hyperthyroidism (HR) subjects with Graves’ disease who received no treatment, ii) patients with SHR; these patients had autoimmune thyroiditis due to positive thyroid antibodies, and iii) euthyroid subjects (EU). There were no statistically significant differences in either body mass index or age between EU and HR and SHR groups (P > 0.05, with one-way ANOVA). The characteristics and the hormonal and metabolic data of the groups are presented in Table 1. None of the subjects was receiving any treatment or had a family history of type 2 diabetes. The female participants were at the first half of their menstrual cycle, and no one was taking oral contraceptives. None of the subjects was receiving any treatment or had a family history of type 2 diabetes. The female participants were at the first half of their menstrual cycle, and no one was taking oral contraceptives. The duration of the disease, as reported by HR patients, was shorter than 3 months. Apart from tachycardia, the duration of the disease, as reported by HR patients, was shorter than 3 months. Apart from tachycardia, no one was taking oral contraceptives.

The characteristics and the hormonal and metabolic data of the groups are presented in Table 1. None of the subjects was receiving any treatment or had a family history of type 2 diabetes. The female participants were at the first half of their menstrual cycle, and no one was taking oral contraceptives. None of the subjects was receiving any treatment or had a family history of type 2 diabetes. The female participants were at the first half of their menstrual cycle, and no one was taking oral contraceptives.

Study protocol

Subjects were admitted to the hospital at 0800 h after an overnight fast and received an OGTT (75 g glucose). Blood samples were drawn before the administration of glucose (at −30 and 0 min) and at 15- to 60-min intervals for 300 min thereafter, and used for measurements of glucose (Yellow Springs Instrument, Yellow Springs, OH, USA) and insulin (RIA, Linco Research, St Charles, MO, USA).

In the fasting state, insulin resistance was estimated by the homeostasis model assessment index (HOMA, (fasting glucose x fasting insulin/22.5)) (12), while in the post-glucose state, insulin sensitivity was estimated by the Matsuda index (10 000/SQRT mean glucose_0_120 x mean insulin_0_120 x fasting glucose x fasting insulin) (13) and the Belfiore index (2/(GlucAUC_0_120/meanGlucAUC_0_120) x (InsAUC_0_120/MeanInsAUC_0_120)) + 1) (14).

At −30 min. 20 ml of blood were drawn for the isolation of mononuclear cells to assess i) GLUT3 and GLUT4 glucose transporter levels on the monocyte plasma membrane in response to insulin, and ii) insulin-stimulated rates of glucose transport.

Effect of insulin on GLUT expression and 6-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl) amido]-6-deoxyglucose uptake: flow cytometry analysis

Insulin exerts its action at a cellular level by numerous steps of intracellular mechanism, the insulin signaling pathway. Regarding glucose transport, the final step

### Table 1: The characteristics, the clinical data, and the indices of insulin resistance of the groups involved in the study. Data are presented as mean values ± S.E.M.

<table>
<thead>
<tr>
<th></th>
<th>EU</th>
<th>HR</th>
<th>SHR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44 ± 4.5</td>
<td>44.25 ± 2.9</td>
<td>43.2 ± 4</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>24.28 ± 0.47</td>
<td>24.85 ± 0.8</td>
<td>24.6 ± 1.26</td>
</tr>
<tr>
<td>FT₃ (pg/ml)</td>
<td>2.94 ± 0.1</td>
<td>9.28 ± 1.1</td>
<td>4.7 ± 0.16</td>
</tr>
<tr>
<td>FT₄ (ng/ml)</td>
<td>1.23 ± 0.07</td>
<td>3.09 ± 0.26</td>
<td>1.83 ± 0.137</td>
</tr>
<tr>
<td>T₃ (ng/ml)</td>
<td>1.3 ± 0.06</td>
<td>2.95 ± 0.29</td>
<td>1.54 ± 0.12</td>
</tr>
<tr>
<td>T₄ (μg/dl)</td>
<td>8.13 ± 0.3</td>
<td>15.6 ± 0.87</td>
<td>10 ± 0.96</td>
</tr>
<tr>
<td>TSH (μU/ml)</td>
<td>1.9 ± 0.4</td>
<td>0.01 ± 0.0005</td>
<td>0.06 ± 0.0035</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl)</td>
<td>50 ± 10</td>
<td>61.8 ± 4.7</td>
<td>58.6 ± 2.34</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl)</td>
<td>137 ± 10</td>
<td>144.5 ± 12.4</td>
<td>140.8 ± 1.7</td>
</tr>
<tr>
<td>Triglycerides (mg/dl)</td>
<td>82 ± 10</td>
<td>80.5 ± 15.3</td>
<td>83.7 ± 8.12</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>122 ± 12</td>
<td>130 ± 14</td>
<td>126 ± 10</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>82 ± 3</td>
<td>86 ± 2</td>
<td>85 ± 4</td>
</tr>
<tr>
<td>HOMA index</td>
<td>1.27 ± 0.16</td>
<td>2.81 ± 0.3</td>
<td>2.43 ± 0.38</td>
</tr>
<tr>
<td>Matsuda index</td>
<td>7.76 ± 0.87</td>
<td>4.21 ± 0.41</td>
<td>4.47 ± 0.33</td>
</tr>
<tr>
<td>Belfiore index</td>
<td>1</td>
<td>0.77 ± 0.05</td>
<td>0.85 ± 0.05</td>
</tr>
<tr>
<td>Glucose AUC_0_300 (mg min/dl)</td>
<td>27 119 ± 1156</td>
<td>32 190 ± 1067</td>
<td>31 497 ± 716</td>
</tr>
<tr>
<td>Insulin AUC_0_300 (mU min/l)</td>
<td>7569 ± 743</td>
<td>11 020 ± 985</td>
<td>9565 ± 904</td>
</tr>
<tr>
<td>n (number of females/males)</td>
<td>12 (8/4)</td>
<td>16 (12/4)</td>
<td>10 (7/3)</td>
</tr>
</tbody>
</table>

*P < 0.05, †P < 0.01, ‡P < 0.001.
of insulin signaling is the enrichment of plasma membrane with GLUT3 and GLUT4 isoforms. Surface glucose transporter isoforms were determined after incubating cells with insulin and staining them with anti-GLUT antisera. In summary, mononuclear cells were aliquoted at the desired concentration (1×10^6 cells/ml) and incubated for 60 min, at 22 °C, in a buffer (NaCl 140 mM, HEPES 20 mM, KCl 5 mM, MgSO_4_2.5 mM, and glucose 5.5 mM, pH 7.4), containing different concentrations of insulin (Sigma Diagnostics). Termination of incubation was achieved with the addition of cytochalasin-B (10 μM; Sigma Diagnostics). Cells were then stained with specific antiserum for GLUT3 and GLUT4, and were analyzed by flow cytometry as described previously in detail (15).

For the glucose transport experiments, the tracer used to monitor glucose flux in monocytes was 6-[N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino]-6-deoxyglucose (NBDG, Invitrogen). Cells were suspended in the above-mentioned buffer at the same concentration. Flow cytometric analysis was initiated immediately after the addition of NBDG (final concentration 30 μM) and insulin. The uptake of the fluorescent probe was recorded as mean fluorescence intensity (MFI) during a 500 s interval, when the reaction reached a plateau (15).

Statistical analysis

Grouped data are expressed as mean±S.E.M. 6-NBDG uptake is presented as an increase over baseline (MFI of cells prior to the addition of the fluorescent analog). The statistical analysis was performed by the statistic software GraphPad InStat (San Diego, CA, USA). The normal distribution of the data was verified by the Kolmogorov and Smirnov method. Insulin dose–response curves were analyzed with repeated-measures ANOVA. Comparison between groups was performed by one-way ANOVA with Bonferroni’s post hoc test.

Results

Postprandial plasma insulin levels were increased in HR patients compared with EU subjects (P<0.05). Postprandial plasma glucose levels were higher in both HR and SHR patients compared with EU (P<0.01 and P<0.05 respectively; Fig. 1).

HOMA index reflects the insulin resistance in the fasting state, while Matsuda and Belfiore indices reflect insulin sensitivity in the postprandial state.

HOMA index was increased in both HR (2.81±0.3) and SHR patients (2.43±0.38) compared with EU subjects (1.27±0.16, P<0.01 and P<0.05 respectively). Belfiore and Matsuda indices were decreased in both HR (0.77±0.05 and 4.21±0.41 respectively) and SHR (0.82±0.04 and 4.47±0.33 respectively) patients compared with EU (1.76±0.87, P<0.001 and P<0.01 respectively).

In monocytes from EU subjects, when insulin was increased from 0 to 100 μU/ml, GLUT4 and GLUT3 isoforms on the plasma membrane increased by 39% (from 194 to 270 MFI) and by 34% (from 301 to 403 MFI) respectively (P<0.0001 with ANOVA for both). The respective increases for the HR patients was 13% (from 318 to 360 MFI, P=0.001 with ANOVA) and 21% (from 388 to 469 MFI, P<0.0001 with ANOVA), while the respective increases for the SHR patients was 12% (from 252 to 309 MFI, P=0.049 with ANOVA) and 22.8% (from 466 to 522 MFI, P=0.021 with ANOVA; Fig. 2).

At 100 μU/ml insulin, GLUT4 levels on the monocyte plasma membrane increased in the HR patients (360 MFI) versus EU subjects (270 MFI, P<0.05), while GLUT3 levels increased in both HR (403 MFI) and SHR patients (522 MFI) compared with EU subjects (403 MFI, P<0.05; Fig. 2).

In monocytes from EU subjects, the 6-NBDG uptake (increases from baseline) in the presence of 0, 25, and 100 μU/ml insulin was increased by 19, 43, and 62% respectively (P<0.005; Fig. 3). The respective increases for HR patients were 26, 34, and 37.8% (P<0.001), while the respective increases for SHR patients were 29.6, 36, and 49.5% (P<0.001; Fig. 3).

At 100 μU/ml insulin, the 6-NBDG uptake in monocytes from HR patients was decreased compared with EU subjects (P<0.05, Fig. 3), while there was no significant change in the monocytes isolated from SHR patients.
Our results demonstrate the presence of insulin resistance not only in HR but also in SHR patients. Increased HOMA and decreased Matsuda and Belfiore indices in HR and SHR patients compared with euthyroid subjects suggest that insulin resistance is present in both fasting and post-glucose state. Our results are in agreement with those of Yavuz et al (7, 8) reporting significantly lower insulin sensitivity in a group of SHR. Interestingly, recent studies have shown that even subtle decreases in the levels of thyroid hormones within the physiological range negatively correlate with the HOMA index (16). These findings, taken together with the results of the present study, suggest that even small deviations from thyroid hormone equilibrium may eventually lead to insulin resistance.

Monocytes provide an easily accessible and reliable model for metabolic studies. These cells have insulin receptors that quickly respond to changes in insulin concentrations and, in the presence of insulin rapidly increase their rates of glucose disposal (15, 17, 18). Moreover, monocytes express all GLUT isoforms found in muscle and adipose tissue, and the increases in glucose transport in response to insulin in these cells correspond well with those observed in tissues quantitatively important for glucose disposal (15, 19). We have previously used monocytes as a cellular model to study insulin sensitivity (11, 15); furthermore, we have suggested the important role of GLUT3 in compensating increased tissue demand for glucose in the HR state (20, 21).

Our data show an elevated basal abundance of GLUT4 and GLUT3 in HR and SHR patients. This is consistent with previous studies on HR patients (20, 21). The increment of expression of GLUT3 and GLUT4 glucose transporters at the basal level of insulin reflects the adaptation of the monocyte to cope with the increased metabolic rates involved in this condition.

In monocytes isolated from HR patients, maximal insulin levels induced an increased GLUT3 and GLUT4 abundance on the monocyte plasma membrane compared with EU subjects; the response in the monocytes isolated from SHR patients was intermediate to that of HR patients and EU subjects (Fig. 2). GLUT3 is not the main insulin-regulated transporter in tissues, but as has been shown (22, 23), the expression of this isoform increases several fold in metabolic stress and increased tissue energy demand; under these conditions, this glucose transporter becomes primarily responsible for the increase in cellular glucose transport and utilization.

Glucose transport controls the rate of glucose utilization and is therefore an important regulatory step in cell metabolism (24). In HR, the absolute rates of insulin-stimulated glucose transport in peripheral tissues (such as muscle or adipose tissue) have generally been found to be normal or increased, in order to adapt to high energy demand (3, 25). However, we have recently shown that glucose uptake in muscle in HR is indeed resistant to insulin, but this defect is masked by a marked increase in blood flow (4); this could be attributed to the dramatic decrease in intracellular pathways of insulin-stimulated glucose metabolism.
Intracellular concentration of calcium. It has been proposed that the HR patients could be attributed to elevated insulin sensitivity. The abundance of GLUT3 and GLUT4 was found intermediate to those of HR and SHR patients. The lack of correlation between the abundance of GLUT3 and GLUT4 in the monocytes of the HR patients could be attributed to increased intracellular concentration of calcium. It has been recently shown that the elevated levels of T3 in HR increase calcium concentration in the cytosol (28). Elevated levels of cytosolic calcium can modulate insulin’s ability to desphosphorylate GLUT4, thus reducing its intrinsic activity and resulting in calcium-induced insulin resistance (29).

In conclusion, HR and SHR are both states of insulin resistance. Both insulin resistance and the increased abundance of GLUT3 and GLUT4, on monocyte plasma membrane of SHR, which were found intermediate to those of HR and EU, are likely explained by the different degrees of thyroid hormone levels. Future research should focus on the insulin signaling cascade and the plausible association of impairment of phosphorylation pattern of signaling molecules (such as insulin receptor substrate 1) with decreased glucose uptake.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This project has been co-funded by the European Social Fund and National Resources – (EPEAEK II) PYTHAGORAS II.

Acknowledgements
We thank E Pappas for technical support and V Fragaki, R N for nursing assistance.

References
13 Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462–1470. (doi:10.2337/diacare.22.9.1462)

www.eje-online.org


